Here’s What Hedge Funds Think About Gilead Sciences, Inc. (GILD)

What have hedge funds been doing with Gilead Sciences, Inc. (NASDAQ:GILD)?

Heading into 2016, a total of 89 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -1% from one quarter earlier. With hedge funds’ sentiment swirling, there exists an “upper tier” of key hedge fund managers who were upping their holdings considerably (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, D. E. Shaw’s D E Shaw has the most valuable position in Gilead Sciences, Inc. (NASDAQ:GILD), worth close to $457 million, comprising 0.7% of its total 13F portfolio. The second most bullish fund manager is Egerton Capital Limited, led by John Armitage, holding a $434.3 million position; 4.5% of its 13F portfolio is allocated to the company. Other hedge funds and institutional investors that hold long positions encompass Cliff Asness’s AQR Capital Management, Samuel Isaly’s OrbiMed Advisors and Donald Chiboucis’s Columbus Circle Investors.